Novel biologic therapies for thymic epithelial tumors.
作者信息
Chen Yuanbin, Gharwan Helen, Thomas Anish
机构信息
Thoracic and Gastrointestinal Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, MD , USA.
出版信息
Front Oncol. 2014 May 7;4:103. doi: 10.3389/fonc.2014.00103. eCollection 2014.
Abstract
摘要
相似文献
1
Novel biologic therapies for thymic epithelial tumors.胸腺上皮肿瘤的新型生物疗法。
Front Oncol. 2014 May 7;4:103. doi: 10.3389/fonc.2014.00103. eCollection 2014.
2
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.贝林司他治疗复发性或难治性晚期胸腺癌患者的 II 期研究。
J Clin Oncol. 2011 May 20;29(15):2052-9. doi: 10.1200/JCO.2010.32.4467. Epub 2011 Apr 18.
3
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.舒尼替尼治疗化疗难治性胸腺瘤和胸腺癌患者：一项开放标签的2期试验。
Lancet Oncol. 2015 Feb;16(2):177-86. doi: 10.1016/S1470-2045(14)71181-7. Epub 2015 Jan 13.
4
Do thymic malignancies respond to target therapies?胸腺恶性肿瘤对靶向治疗有反应吗？
Interact Cardiovasc Thorac Surg. 2015 Jun;20(6):855-9. doi: 10.1093/icvts/ivv040. Epub 2015 Mar 8.
5
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.西妥昔单抗治疗复发性或难治性晚期胸腺癌患者的多中心、开放标签、2 期临床试验。
Lancet Oncol. 2014 Feb;15(2):191-200. doi: 10.1016/S1470-2045(13)70596-5. Epub 2014 Jan 15.
6
Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group.晚期铂类耐药胸腺癌中持续舒尼替尼方案：来自意大利胸腺癌协作组（ThYmic MalignanciEs，TYME）的回顾性分析。
Eur J Cancer. 2022 Oct;174:31-36. doi: 10.1016/j.ejca.2022.07.009. Epub 2022 Aug 12.
7
Primary thymic epithelial neoplasms showing combined features of thymoma and thymic carcinoma. A clinicopathologic study of 22 cases.呈现胸腺瘤和胸腺癌联合特征的原发性胸腺上皮性肿瘤。22例临床病理研究。
Am J Surg Pathol. 1996 Dec;20(12):1469-80. doi: 10.1097/00000478-199612000-00006.
8
[Correlation of amplification of chromosome 1 with histologic typing of thymic epithelial tumors].[1号染色体扩增与胸腺上皮肿瘤组织学类型的相关性]
Zhonghua Bing Li Xue Za Zhi. 2011 Dec;40(12):820-4.
9
A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.贝利司他联合顺铂、多柔比星和环磷酰胺治疗胸腺上皮肿瘤的I/II期试验：一项临床与转化研究
Clin Cancer Res. 2014 Nov 1;20(21):5392-402. doi: 10.1158/1078-0432.CCR-14-0968. Epub 2014 Sep 4.
10
Methylation and expression profiles of MGMT gene in thymic epithelial tumors.MGMT 基因在胸腺瘤中的甲基化和表达谱。
Lung Cancer. 2014 Feb;83(2):279-87. doi: 10.1016/j.lungcan.2013.12.004. Epub 2013 Dec 21.
引用本文的文献
1
Immunotherapy in thymic epithelial tumors: tissue predictive biomarkers for immune checkpoint inhibitors.胸腺上皮肿瘤的免疫治疗：免疫检查点抑制剂的组织预测生物标志物
Explor Target Antitumor Ther. 2024;5(3):465-476. doi: 10.37349/etat.2024.00229. Epub 2024 May 21.
2
Pan-cancer Analysis Reveals SRC May Link Lipid Metabolism and Macrophages.泛癌分析揭示SRC可能与脂质代谢和巨噬细胞相关。
Iran J Biotechnol. 2023 Apr 1;21(2):e3325. doi: 10.30498/ijb.2023.335402.3325. eCollection 2023 Apr.
3
Immunotherapy for thymoma.胸腺瘤的免疫疗法。
J Thorac Dis. 2020 Dec;12(12):7635-7641. doi: 10.21037/jtd-2019-thym-12.
4
Pan-Cancer Landscape Analysis Reveals Recurrent - Gene Fusion in Aggressive Histologic Subtypes of Thymoma.泛癌图谱分析揭示胸腺瘤侵袭性组织学亚型中的复发性基因融合。
JCO Precis Oncol. 2020 Feb 26;4. doi: 10.1200/PO.19.00288. eCollection 2020.
5
Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk?用于治疗胸腺上皮肿瘤的免疫检查点抑制剂：如何最大化获益并优化风险？
Mediastinum. 2019 Sep;3. doi: 10.21037/med.2019.08.02. Epub 2019 Sep 9.
6
WT1 as an immunotherapy target for thymic epithelial tumors: a novel method to activate anti-tumor immunity.WT1作为胸腺上皮肿瘤的免疫治疗靶点：一种激活抗肿瘤免疫的新方法。
Mediastinum. 2019 Apr;3. doi: 10.21037/med.2019.03.03. Epub 2019 Apr 8.
7
Uncommon efforts for an uncommon tumor: the case for development of newer systemic therapies for advanced thymic epithelial tumors.为罕见肿瘤付出非凡努力：开发晚期胸腺上皮肿瘤新型全身治疗方法的理由
Mediastinum. 2018 Mar;2. doi: 10.21037/med.2018.03.04. Epub 2018 Mar 13.
8
The Integrated Genomic Landscape of Thymic Epithelial Tumors.胸腺癌的综合基因组景观。
Cancer Cell. 2018 Feb 12;33(2):244-258.e10. doi: 10.1016/j.ccell.2018.01.003.
9
Expression of mesothelin in thymic carcinoma and its potential therapeutic significance.间皮素在胸腺癌中的表达及其潜在治疗意义。
Lung Cancer. 2016 Nov;101:104-110. doi: 10.1016/j.lungcan.2016.09.015. Epub 2016 Sep 28.
10
Novel Treatments for Thymoma and Thymic Carcinoma.胸腺瘤和胸腺癌的新型治疗方法
Front Oncol. 2015 Nov 30;5:267. doi: 10.3389/fonc.2015.00267. eCollection 2015.
本文引用的文献
1
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.西妥昔单抗治疗复发性或难治性晚期胸腺癌患者的多中心、开放标签、2 期临床试验。
Lancet Oncol. 2014 Feb;15(2):191-200. doi: 10.1016/S1470-2045(13)70596-5. Epub 2014 Jan 15.
2
Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma.索拉非尼治疗广泛预处理的胸腺癌患者的长期疗效。
Target Oncol. 2012 Dec;7(4):247-51. doi: 10.1007/s11523-012-0235-8. Epub 2012 Oct 23.
3
Imatinib mesylate in thymic epithelial malignancies.甲磺酸伊马替尼治疗胸腺瘤上皮性肿瘤。
Cancer Chemother Pharmacol. 2012 Feb;69(2):309-15. doi: 10.1007/s00280-011-1690-0. Epub 2011 Jun 28.
4
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.贝林司他治疗复发性或难治性晚期胸腺癌患者的 II 期研究。
J Clin Oncol. 2011 May 20;29(15):2052-9. doi: 10.1200/JCO.2010.32.4467. Epub 2011 Apr 18.
5
Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas.胰岛素样生长因子-1 受体和磷酸化 AKT 丝氨酸 473 在 132 例切除的胸腺瘤和胸腺癌中的表达。
Cancer. 2010 Oct 15;116(20):4686-95. doi: 10.1002/cncr.25367.
6
Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.舒尼替尼治疗转移性胸腺癌：实验室发现和初步临床经验。
Br J Cancer. 2010 Jul 13;103(2):196-200. doi: 10.1038/sj.bjc.6605740. Epub 2010 Jun 22.
7
Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.甲磺酸伊马替尼治疗世界卫生组织 B3 型胸腺瘤和胸腺癌患者。
J Thorac Oncol. 2009 Oct;4(10):1270-3. doi: 10.1097/JTO.0b013e3181b6be57.
8
Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.全面的基因组分析揭示了胸腺癌和胸腺瘤之间具有临床意义的分子差异。
Clin Cancer Res. 2009 Nov 15;15(22):6790-9. doi: 10.1158/1078-0432.CCR-09-0644. Epub 2009 Oct 27.
9
Apoptosis-related (survivin, Bcl-2), tumor suppressor gene (p53), proliferation (Ki-67), and non-receptor tyrosine kinase (Src) markers expression and correlation with clinicopathologic variables in 60 thymic neoplasms.60例胸腺肿瘤中凋亡相关蛋白（存活素、Bcl-2）、肿瘤抑制基因（p53）、增殖指标（Ki-67）及非受体酪氨酸激酶（Src）标志物的表达及其与临床病理变量的相关性
Chest. 2009 Jul;136(1):220-228. doi: 10.1378/chest.08-2482. Epub 2009 Mar 24.
10
Optimal therapy for thymoma.胸腺瘤的最佳治疗方法。
J Med Invest. 2008 Feb;55(1-2):17-28. doi: 10.2152/jmi.55.17.
Zotero 插件